Drug Registration in Russia

drug registration EAEU

 Overview of drug registration in Russia

The Russian pharmaceutical industry is expected to exceed two trillion Russian rubles in 2020, representing a roughly 10% growth over the previous year. Pharmaceutical revenues are expected to reach 2.35 trillion Russian rubles by 2023. It’s also worth noting that permission times are among the quickest in the globe (Statista). However, bear in mind that Russian pharmaceutical law is not always in sync with international standards. This is the first of two blogs on drug registration in Russia, and it focuses on:

  1. Regulatory Authorities 
  2. Good Manufacturing Practices in Russia
  3. Non-clinical Studies
  4. Running Local Clinical Trials in Russia
  5. Clinical Trials Application in Russia

Previous legislation was mandated by the Federal law on the distribution of medical goods, passed in 2010. However, sice the end of 2020, the national authorization process would no longer be in force. As a result, there are few legislative and regulatory provisions. Furthermore, regulatory rules in the pharmaceutical industry often duplicate but do not evolve legislative laws. Thus such regulatory clauses may be regarded as superfluous. Again, pharmaceutical law differs from other types of healthcare product legislation, such as medical device or cosmetics rules. Many contentious elements are included in the law. However, they are not applied or enforced. For instance, legal definitions of bioequivalence studies or generics, for example, are not followed, and human and veterinary requirements are merged in one legislation.

 

Who are the authorities for Marketing Approval 

In comparison to other countries and areas, the Russian regulation framework for healthcare items is fairly fragmented. At least four distinct competent authorities are involved in drug registration in Russia.

 

Russian Ministry of Health

The Russian Ministry of Health is responsible for granting marketing authorization, clinical trial applications, and price control over certain medicinal products included in the Russian Essential Medicines List. In addition, the Ministry of Health has has a specific government institution; the FGBU. This institution assesses marketing authorization application dossiers and other types of dossiers such as clinical trial application dossiers, variation, or renewal dossiers.

 

Russian Ministry of Industry and Trade

The second government agency important for regulating medicinal products for human use is the Ministry of Industry and Trade. This institution is responsible for issuing manufacturers’ authorizations for local establishments and GMP certification of manufacturing facilities in Russia and abroad.

 

Roszdravnadzor

The next crucial regulatory player is Roszdravnadzor, the Russian abbreviation for the Federal Agency for Healthcare and Social Development Supervision. This institution:

  1. overseas pharmacovigilance of human pharmaceuticals 
  2. carries out the GCP inspections
  3. conducts GLP inspections (limited to human drugs)
  4. is responsible for official batch release testing 

 

Federal Antitrust Service

The Federal Antitrust Service completes the list of Russia’s principal regulators of human drugs. It regulates pharmaceutical advertising in foreign markets and sets prices for medications on the Russian Essential Medicines List. Additionally, it plays a crucial part in the decision-making process associated with the development of new pharmaceutical legislation.

 

Good Manufacturing Practices in Russia

GMP accreditation is a significant concern for foreign pharmaceutical companies. To apply for a marketing authorization in Russia, you must possess a valid Good Manufacturing Practices (GMP) certificate from the Russian Federation; overseas GMP certificates are not recognized. It makes no difference whether the maker is based in an ICH or PIC/S Member State.

However, a GMP certificate issued by a member state of the Eurasian Economic Union (EAEU) (Belarus, Kazakhstan, Armenia, or Kyrgyzstan) is accepted as proof of compliance with Russian GMP requirements. The GMP Inspectorate is housed inside the Ministry of Industry and Trade; it is a distinct government entity known as the Federal Budgetary Institution that is responsible for the State Institute of Medicinal Products and Good Practices.

The inspection application process is unrelated to the granting of marketing permission. If no GMP certificate issued by the Ministry of Industry and Trade exists, a marketing license application may still be submitted if the business provides confirmation from the Pharmaceutical Inspectorate that the inspection will occur in the future. Marketing authorization will be postponed in this situation until you produce a valid GMP certificate following evaluation by the Russian GMP Inspectorate.

 

How does Russian GMP compare to EU?

The Russian GMP Order is based on the European Union’s Good Manufacturing Practice rules, which are contained in EudraLex – Volume 4. Specifically, the Glossary, Parts I–III, and Part I Annexes were translated. However, various adjustments were made, resulting in a little divergence between Russian and EU norms.

It is worth mentioning that when the Russian version of GMP was drafted, the government placed a premium on technical components of good manufacturing practices while mainly ignoring procedural ones. This resulted in procedural ambiguity, which must be rectified.

For example, the GMP Order lacks provisions similar to those included in Titles IV and XI of Directive 2001/83/EC, European Union Directive 1572/2017, and national requirements of EU Member States, such as those found in the United Kingdom’s 2012 Human Medicines Regulations.

 

Timelines for Russian GMP Certificate

Due to the fact that GMP laws became effective relatively recently, the quantity of applications for GMP certificates has exceeded the Inspectorate’s operational capacity, resulting in the creation of a waiting list with a huge wait period of six to twelve months.

As a result, it is critical to examine GMP certification enough in advance of submitting an application for marketing permission. Also, certificated need to be renewed at least once every three years, and renewal inspections are required. However, the scope of the examination may be set by the risk-based approach.

The Ministry of Health will reject a marketing permission application if the appropriate production facilities have not been inspected for GMP compliance. Before requesting for marketing license, an applicant must negotiate and approve the inspection date with the Ministry of Industry and Trade and the GMP Inspectorate.

Occasionally, international makers of finished products may encounter difficulties during product-specific inspections, as Russia’s primary quality control document is a normative document that frequently differs from the manufacturer’s specification.

 

Normative document in Russia

The Russian State Pharmacopoeia serves as the foundation for the normative document., and isn’t harmonized with other pharmacopoeias; also, assessors frequently make recommendations to improve the normative document’s analytical procedures. These suggestions, however, are based on testing findings produced in the official laboratory, which does not conduct validation or method transfer when verifying the applicant’s test procedures. Our specialists will gladly discuss a viable method for you to facilitate this procedure, assisting you in minimizing risk and overcoming obstacles associated with obtaining a certificate for medication registration in Russia.

 

Non-Clinical Studies for drug registration in Russia

Non-clinical test data may be required in some situations when submitting an clinical trial application, applying for marketing authorization, or and extenson/renewal of a medical product. Nonetheless, there are a few unique difficulties. To begin, federal regulations require that all non-clinical experiments be completed under GLP.

So, non-clinical PD and PK testing also need to adhere to GLP standards; this is typically not practicable. However, because this compliance is typically not monitored by the regulator, no difficulties have developed as a result of this issue thus far. Nonetheless, keep in mind that you must adequately explain this to regulators or assessors in the event of observations. It is essential to say that Russia has two GLP systems that do not agree with each other:

  1. GLP general laws that adhere to the OECD’s GLP guidelines
  2. Secondly, there is the pharmaceutical-specific GLP Order, which is a significantly condensed version of the OECD GLP standards.

Because the OECD GLP recommendations cover Russian pharmaceutical-specific GLP rules, there should be no issues in this area if an applicant follows the OECD GLP guidelines while conducting non-clinical studies.

The following probable issue is a necessity for generic or hybrid applications to submit non-clinical test data. (In certain cases, hybrid applications are referred to as IMD or incrementally modified medications.) Although this need is outmoded and in some cases may be superseded by thorough bibliographic data, similar observations continue to emerge and may be addressed through detailed explanation and bibliographic data. Two to four weeks of subacute toxicity and local tolerance trials are typically required. Naturally, it is preferable to address these concerns and examine your choices for continuing without the additional in-vivo testing.

 

Local Clinical Trials

Russian regulations require that at least one clinical trial be conducted on Russian clinical facilities. However, in multi-site trials, one Russian site may be added to comply with local clinical trial requirements.

The statute expressly excludes the possibility of replicating or implementing the complete clinical development program in Russia. Additionally, there is no obligation to conduct the entire phase (i.e. numerous CTs) of a clinical development program. Finally, a clinical trial is considered a bioequivalence research. Due to the fact that it is rarely suitable to split a bioequivalence study across multiple clinical locations, a complete study must be done or repeated in Russia for generic products. In other circumstances, an international multicenter clinical study is the most practicable alternative.

Simultaneously, early phase (phase 1) trials in healthy participants using clinical trial material manufactured abroad are not permitted. These provisions safeguard healthy individuals against the testing of previously untested chemicals on healthy Russian human beings. However, such research are permissible when patient participants are involved. Thus, where a Phase 1 trial in healthy volunteers is desired, it is preferable to find a Russian partner capable of running at least one production step (for example, packaging).

Clinical trials must adhere to the Russian GCP Order, which is based on ICH GCP(R1) but is less severe. However, while compliance with GCP is not critical for the Ministry of Health and assessors, a simple declaration of compliance may suffice.

 

When is there no need for Clinical Trials in Russia?

Applicants are exempt from sharing data from local clinical trials in a number of circumstances. These are the circumstances set forth in Article 18 of the Federal law.

If you conducted a trial in Belarus

Interestingly, the relation between Russia and Belarus is noticeable in drug registration in Russia. If a clinical trial was conducted in Belarus, such a trial counts for a local clinical trial because Russia has a close connection with this Republic. 

Generics

Additionally, certain generic drugs are exempt from the requirement to provide clinical trial data in order to meet certain biowaiver criteria, whether local or national. For instance, oral or parenteral solutions or medicinal gases may be permitted only once pharmaceutical equivalency data are obtained. Additional strengths may also be approved without clinical data, albeit this sort of biowaiver is not permitted by federal standards. Because the regulation has no formal criteria for increased strength biowaivers, assessors must determine the applicability of this sort of biowaiver on an individual basis.

Orphan Drugs

First, orphan medicinal products are exempt from local clinical trials, so no local clinical data is needed if a drug product is recognized in Russia as an orphan.

Combination Products

For certain combination products, no additional clinical data is needed as provided in the legislation. In these cases, the bibliographic data might be sufficient. Local clinical trials are also unnecessary where new uses or indications are added for an authorized medicinal product.

 

The Clinical Trial Application for Drug Registration in Russia

The duration of the CTA procedure is only 30 business days, and the requirements for clinical trial applications are rather loose. For instance, an investigational medicinal product dossier is not needed. you only need to provide clinical documents concerning the clinical trial application dossier like the:

  • Study protocol
  • Investigator’s Brochure
  • Informed Consent Form
  • Case Report Form
  • Insurance policy
  • Etc.

A quality conformance certificate for the investigational product is sufficient in a CTA dossier. No Investigational Medicinal Products Dossier or other documents sufficiently detailing quality aspects of the investigational product is needed. Generally, scientific standards for the design and conduct of clinical studies are in line with internationally accepted approaches as outlined in ICH, EMA, WHO, or FDA guidelines and guidance documents.

At least one request for additional information and/or data may be sent to the applicant during the procedure to which you need to respond within a maximum of 90 business days. Fail to do so, and the Ministry of Health concludes the process based on your initially submitted application data.

Next steps in drug registration in Russia

The next step in registration is a state procedure to assess drug quality, efficiency, and safety evaluation to obtain approval for medical use of a drug in the Russian Federation. Which is discussed in Part 2 of that describes how to gain Marketing Authorization in Russia.

To help you prepare and justify the applicability of exemptions and waivers, we’d be happy to our expertise. It might save you costly efforts.

Start a conversation with one of our experts here. 

 

Clinical Study Start-up: Is there any Difference Between Western and Eastern Europe?

Clinical Study Start-up: Is there any Difference Between Western and Eastern Europe?

Medicine is constantly evolving to invent effective ways to treat diseases. This progress is a never-ending process: life science industry develops new molecules and treatments and improves existing ones continually. Experimentation and testing have long been a part of medicine, and it is up until now as clinical trials have an essential part in the development of new treatments. These reasons allow us to assume that the relevance of clinical trials will not diminish in the future.

read more
Running a Clinical Trial in Ukraine

Running a Clinical Trial in Ukraine

Despite the fact that Ukraine is the largest country in Eastern Europe with a large population of treatment-naïve patients, well organized public health care sector and significant number of medical sites accredited for clinical trial conduction, country has utilized only 15% of its current potential for hosting clinical trials. During 2017, the European Medicine Agency (EMA) gave positive recommendations on 94 new drug applications and 49 of them were tested in clinical trials in Ukraine. During the same year, the US FDA approved 151 new drugs, and 28 of them were also studied in Ukraine.

read more
What You Need to Know about Running a Clinical Trial in Russia?

What You Need to Know about Running a Clinical Trial in Russia?

Russia is a very perspective country for international clinical trial conduction. The first international clinical trial was set up in Russia about 20 years ago only, and from than country kept a great potential for market development. In 2018 health authorities (HAs) approved 653 clinical trials (CT) in Russian Federation, less in overall numbers compared to the same indicator from 2016 – 898 approved CTs. However, this decrease was observed across all types of clinical trials except for international multicentre clinical trials (IMCT).

read more
The CIS Region: Excellent Potential for Patient Recruitment but is there any Risk to Quality?

The CIS Region: Excellent Potential for Patient Recruitment but is there any Risk to Quality?

The number of clinical trials worldwide is increasing more than 10% each year due to the new diseases, further research for better health products and development of new drugs. Though, for a successful clinical trial, there is a major challenge – patient recruitment, which is essential and the most challenging factor due to the increasing number of new clinical trials. In order to achieve the required patient recruitment, sponsors are looking for different solutions.

read more
5 things you need to know about running a clinical study in the Baltic states

5 things you need to know about running a clinical study in the Baltic states

In the past five years, an average of 175 clinical trials are being initiated in the Baltic states each year. An average of 64,8% of the population in the Baltic states are in the age from 15 to 65 years old, the main target audience for clinical trials. Furthermore, a large pool of treatment-naïve subjects is available compared to other EU countries or the US. Patients with special therapeutic diseases are transferred to the main central hospitals.

read more
Remaining Vigilant and Compliant after Brexit: What’s next? (Latest Updates)

Remaining Vigilant and Compliant after Brexit: What’s next? (Latest Updates)

On 29th March 2017 UK submitted the notification of its intention to withdraw from the EU. This means that UK will become a ‘third country’ from 30th March’19. Even though leaving the EU with a deal remains the Government’s top priority, UK drug agency is publishing a series of guidance documents for industry and other stakeholders covering the proposed arrangements for the regulation of medicines, medical devices and clinical trials, if UK leaves EU with no deal.

read more
Tuberculosis Medicines Clinical Development in Eastern Europe and CIS

Tuberculosis Medicines Clinical Development in Eastern Europe and CIS

World Tuberculosis Day is commemorated every year on 24th March to raise awareness of tuberculosis, which is still causing death of nearly 1.5 million people each year, mostly in developing countries. It marks the day in 1882, when Dr. Robert Koch announced that he had discovered the cause of tuberculosis, the TB bacillus. In comparison to other infectious diseases caused by a single infectious agent, tuberculosis is the second biggest killer worldwide.

read more